Stay updated on Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an increase in the number of study subjects enrolled in the clinical trial investigating Poly-ICLC in combination with Anti-PD-1 or Anti-PD-L1 for the treatment of advanced solid cancers.
    Difference
    0.1%
    Check dated 2024-06-06T14:21:58.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.' This change provides a more detailed explanation of the eligibility criteria for participation in the study.
    Difference
    40%
    Check dated 2024-05-22T21:00:46.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:21:43.000Z thumbnail image

Stay in the know with updates to Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Poly-ICLC and Anti-PD1 Combo in Melanoma Clinical Trial page.